openPR Logo
Press release

Tendinitis Pipeline Assessment 2023: Clinical Trials, Therapies and Key Companies involved by DelveInsight | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics and Others.

03-16-2023 10:51 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Tendinitis Pipeline

Tendinitis Pipeline

DelveInsight's, "Tendinitis Pipeline Insight, 2023" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Tendinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Click here to know more about Tendinitis Pipeline report offering @ https://www.delveinsight.com/report-store/tendinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Tendinitis Overview:
Tendinitis is an inflammation of a tendon, a group of sturdy fibers that connects a muscle to the nearby bone. Another commonly used term for tendinitis is tendinopathy. Tendinitis is generally caused by injury, trauma, or overuse of a joint. Tendinitis may be referred to by a more specific description depending on the location where it occurs, such as Achilles tendinitis or tennis elbow. The elbows, heel, shoulder and wrist are common locations for tendinitis. Tendinitis is treated with rest along with medications to relieve pain and reduce inflammation. Physical therapy can be helpful to improve muscle strength and enhance healing. In some cases, surgery will need to be performed to repair tendon damage.

Some of Tendinitis Companies are:
• Seikagaku Corporation
• MetrioPharm
• MiMedx
• Zhejiang Xingyue Biotechnology Co., Ltd.
• R3 Stem Cell
• Dobecure
• Causeway Therapeutics
• And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/tendinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's Tendinitis report covers around 4+ products under different phases of clinical development like:
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of Tendinitis Therapies are:
• SI-613
• MP1032
• dHACM
• And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/tendinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Current Tendinitis Treatment Scenario and Tendinitis Emerging Therapies:
• How many companies are developing Tendinitis drugs?
• How many Tendinitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tendinitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tendinitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tendinitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Request for Free Sample Report: https://www.delveinsight.com/sample-request/tendinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents:
Introduction
Executive Summary
Tendinitis: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Tendinitis - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Tendinitis Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
dHACM: MiMedx
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
MP 1032: MetrioPharm
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Tendinitis Key Companies
Tendinitis Key Products
Tendinitis- Unmet Needs
Tendinitis- Market Drivers and Barriers
Tendinitis- Future Perspectives and Conclusion
Tendinitis Analyst Views
Tendinitis Key Companies
Appendix

Request for Free Sample Report: https://www.delveinsight.com/sample-request/tendinitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting/primary-research-services

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tendinitis Pipeline Assessment 2023: Clinical Trials, Therapies and Key Companies involved by DelveInsight | Seikagaku Corporation, MetrioPharm, MiMedx, Zhejiang Xingyue Biotechnology Co., Ltd., R3 Stem Cell, Dobecure, Causeway Therapeutics and Others. here

News-ID: 2977870 • Views:

More Releases from DelveInsight Business Research

Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by 240,000+ Diagnosed Cases Across 7MM, estimates DelveInsight
Limbal Stem Cell Deficiency Market to Surpass USD 2.6 Billion by 2034, Driven by …
In 2023, the Limbal Stem Cell Deficiency (LSCD) market was dominated by the United States, generating nearly USD 1.5 billion in revenue, while Spain represented the smallest market with approximately USD 127 million. This regional distribution is expected to remain consistent throughout the forecast timeline. The US accounted for nearly 103,000 diagnosed LSCD cases, whereas Japan recorded around 37,000 cases, with both countries projected to witness notable growth in patient
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Therapies, estimates DelveInsight
SSc-ILD Market Set to Cross USD 750 Million by 2034, Driven by 10+ Emerging Ther …
The major players operating in the Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) market include Roche, Prometheus Biosciences, Inc., Merck, GlaxoSmithKline, Genentech, Inc., Acceleron, Boehringer Ingelheim, Actelion, Hôpital Claude-Huriez, Changchun GeneScience Pharmaceutical, among others. DelveInsight's report titled "Systemic Sclerosis-associated Interstitial Lung Disease Market Insights, Epidemiology, and Forecast-2034" delivers a comprehensive analysis of SSc-ILD, covering historical data, projected epidemiology, and evolving market trends across the United States, EU4 (Germany, Spain, Italy, and France),
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerated Expansion, Fueled by Targeted Therapies and a Growing Innovation Pipeline, Says DelveInsight
Developmental and Epileptic Encephalopathy Treatment Market Poised for Accelerat …
The Developmental and Epileptic Encephalopathy (DEE) treatment market across the seven major markets (7MM) was valued at nearly USD 2.1 billion in 2023 and is expected to register a healthy compound annual growth rate over the forecast period. The United States emerged as the largest contributor, capturing close to 80% of the overall market revenue. The DEE treatment landscape is undergoing a significant transformation as the limitations of traditional antiepileptic drugs
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Companies Reshaping the Treatment Landscape, estimates DelveInsight
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ Therapies and 8+ Co …
DelveInsight's "Polycythemia Vera Pipeline Insight 2025" report delivers an in-depth overview of the Polycythemia Vera pipeline landscape, covering more than 8 companies and 10+ pipeline candidates. The report analyzes both clinical-stage and preclinical assets, offering detailed drug profiles across various stages of development. It also evaluates Polycythemia Vera therapies based on product classification, development stage, route of administration, and molecular category, while additionally spotlighting inactive or discontinued pipeline assets. Explore the

All 5 Releases


More Releases for Tendinitis

Patellar Tendinitis Market Growth Outlook: Current Scenario, Future Trends, and …
" The Patellar Tendinitis Market is experiencing significant growth, driven by a confluence of factors including increasing participation in sports and recreational activities, a rising geriatric population more susceptible to tendon injuries, and advancements in diagnostic and treatment modalities. Technological advancements, such as improved imaging techniques (MRI and Ultrasound) and minimally invasive surgical procedures, are enabling more accurate diagnoses and effective treatments. Furthermore, the development and adoption of regenerative therapies, like
05-01-2025 | Health & Medicine
Getnews
Capitol Physical Therapy Releases In-Depth Report on Shoulder Tendinitis
Image: https://www.globalnewslines.com/uploads/2025/05/1746062899.jpg Capitol Physical Therapy, a Washington D.C. physical rehabilitation therapy clinic [https://capitolptdc.com/], has released a new educational report on a common condition that affects millions each year: shoulder tendinitis. This comprehensive guide aims to help individuals better understand the condition and how physical therapy can play a key role in recovery and long-term prevention. "We use our shoulders for nearly everything - reaching, lifting, throwing, and more," the report says. "But
Chesapeake Foot & Ankle Institute Announces New Report on Achilles Tendinitis
Image: https://www.globalnewslines.com/uploads/2025/03/1741050325.jpg The Chesapeake Foot & Ankle Institute [https://chesapeakefai.com/] is proud to announce the release of a comprehensive report addressing the common but often misunderstood condition of Achilles tendinitis. This new report aims to provide individuals with essential insights into the Achilles tendon, how injuries occur, and how those suffering from the condition can find relief. The Achilles tendon, located at the back of the lower leg and connecting the calf muscles
Tendinitis Treatment Market Is Booming Worldwide with Sandoz, Perrigo, Akron
The "Global Tendinitis Treatment" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global Tendinitis Treatment provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study
Tendinitis Treatment Market Size, Industry Outlook and Forecast to 2028
The report “Global Tendinitis Treatment Market Growth 2021-2028” from Databridge Market Research includes data and information about market structure and size. The purpose of this research is to give market knowledge and strategic insights to assist in decision making, making informed investment decisions, and identifying potential growth opportunities. Download Free Sample Report: To Know The Impact Of COVID-19 On This Industry @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-tendinitis-treatment-market The Global Tendinitis Treatment Market market report also indicates
Tendinitis Treatment Market Size - Forecast to 2026
As per the research conducted by GME, the Tendinitis Treatment Market is estimated to be valued at USD 6.46 Billion in 2021 and is projected to reach USD 9.42 Billion by 2026 at a CAGR of 7.85%. The rapidly evolving healthcare industry, soaring healthcare spending, the growing proportion of the aging demographic demanding preventive care, technological enhancement in therapies and prognosis, and expanding government subsidies are notable driving elements for